---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Perspective and time frame"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Perspective and time frame. Topics: Pegcetacoplan PBAC financial estimates: payer perspective and 6-year horizon; Avacincaptad pegol PBAC financial estimates: population projections, 2027 to 2032. 2 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics/perspective-and-time-frame"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Perspective and time frame

<a id="heading-4.2.2"></a>

## 4.2.2 Perspective and Time Frame

<a id="topic-4.2.2-1"></a>

### Budget impact model of vonaprument: perspective and time frame

No evidence found.

<a id="topic-4.2.2-2"></a>

### Pegcetacoplan PBAC financial estimates: payer perspective and 6-year horizon

> “The total cost to the PBS/RPBS of listing pegcetacoplan was estimated to be $50 million to < $60 million in Year 6, and a total of $200 million to < $300 million in the first 6 years of listing.”

Source: [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)

<a id="topic-4.2.2-3"></a>

### Avacincaptad pegol PBAC financial estimates: population projections, 2027 to 2032

> “ABS population projections, 2027-2032 (base year 2022) for individuals aged ≥ 50 years old.”
> “Net cost to PBS/RPBS/MBS”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
